预约演示
更新于：2025-12-01
Metoclopramide Hydrochloride
盐酸甲氧氯普胺
更新于：2025-12-01
概要
基本信息
简介甲氧氯普胺是一种多巴胺-2（D2）拮抗剂的小分子药物。用于治疗胃食管反流病（GERD）和急性或复发性糖尿病胃轻瘫（胃淤滞）等疾病，该药最初由赛诺菲开发，于1967年3月首次在日本批准使用。是一种可用于口服和注射的药物。 |
药物类型 小分子化药 |
别名 2-methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide、2-methoxy-5-chloroprocainamide、4-amino-5-chloro-2-methoxy-N-(β-diethylaminoethyl)benzamide + [32] |
靶点 |
作用方式 拮抗剂 |
作用机制 DRDs拮抗剂(多巴胺受体家族拮抗剂) |
在研适应症 |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H25Cl2N3O3 |
InChIKeyKJBLQGHJOCAOJP-UHFFFAOYSA-N |
CAS号54143-57-6 |
关联
269
项与 盐酸甲氧氯普胺 相关的临床试验ChiCTR2500112941
Professor Jia Yingjie's "Eliminating Dregs and Cultivating the Root" Acupuncture Method for Treating Postoperative Gastric Emptying Disorder after Whipple Procedure
NCT07208305
Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting
CTR20253397
甲氧氯普胺片（10 mg）在餐后状态下健康人体生物等效性研究
100 项与 盐酸甲氧氯普胺 相关的临床结果
登录后查看更多信息
100 项与 盐酸甲氧氯普胺 相关的转化医学
登录后查看更多信息
100 项与 盐酸甲氧氯普胺 相关的专利（医药）
登录后查看更多信息
7,416
项与 盐酸甲氧氯普胺 相关的文献（医药）2025-12-01Journal of the American Medical Directors Association
Parkinson's Disease Medication Administration Timing Deviations and Contraindicated Medicine Use in Residential Aged Care: A Retrospective Cohort Study
Article
作者: Westbrook, Johanna I ; Timothy, Andrea ; Raban, Magda Z ; Urwin, Rachel ; Neupane, Sangita ; Wabe, Nasir
OBJECTIVES:
Parkinson's disease (PD) is a common condition among older people and requires tailored, time-sensitive pharmacologic therapy for optimal symptom management. No prior studies have examined the extent to which doses of time-critical PD medicines are delayed or missed in residential aged care (RAC) settings. We aimed to identify deviations in PD medication administration timing and the use of medicines that are contraindicated in PD.
DESIGN:
A retrospective longitudinal cohort study.
SETTING AND PARTICIPANTS:
Twenty-three RAC facilities in New South Wales, Australia. Permanent residents aged ≥65 years who received PD medicines.
METHODS:
Routinely collected electronic data from January 1 to September 30, 2024, was used to investigate deviations in PD medication administration timing, defined as the difference between scheduled and actual administration times. We quantified the extent of dose administration timing deviation using 30-minute and 60-minute thresholds. The proportion of residents prescribed medicines contraindicated in PD, based on the Beers Criteria, was determined.
RESULTS:
A total of 202 permanent residents (7.9% of all residents) received PD medicines. All 202 residents experienced at least 1 instance of dose timing deviations of >30 minutes, and almost all (98%) experienced a deviation of >60 minutes during the 9-month study. Of 166,028 scheduled doses, 1.1% (n = 1776) were not administered and 72.8% of residents (n = 147) missed at least 1 dose. Of 164,252 total administered doses of PD medicines, 25.6% (n = 42,069) were given >30 minutes before or after the scheduled time, equivalent to 605.8 incidents of wrong timing per 1000 resident days (95% CI, 572.0-641.6). Contraindicated medicines were given to 12.4% of residents (n = 25) who received PD medicines. The most commonly administered contraindicated medicines were metoclopramide (9 of 25, 36%), risperidone (8 of 25, 32%) and aripiprazole (5 of 25, 20%).
CONCLUSIONS AND IMPLICATIONS:
Our study identified extensive deviations in dose timing of PD medicines in RAC. Implementing strategies to enhance adherence to prescribed schedules for time-critical treatments may improve symptom management for residents with PD and reduce additional negative health outcomes and associated health care costs.
2025-12-01JOURNAL OF ADOLESCENT HEALTH
Cannabinoid Hyperemesis Syndrome in Adolescents: The Role of Aprepitant as a New Treatment Option for Rapid Symptom Relief
Article
作者: Carroll, Taryn ; Sigal, Anat ; Mautone, Susan G ; Padilla, Gabrielle
Cannabinoid hyperemesis syndrome (CHS) is a growing clinical concern among adolescents, which is marked by recurrent episodes of nausea, vomiting, and abdominal pain related to chronic cannabis use. Treatment remains challenging, particularly when symptoms persist despite conventional antiemetics such as ondansetron, metoclopramide, haloperidol, and capsaicin. This case report describes two adolescents who presented with symptoms consistent with the Rome IV criteria for CHS and a documented history of chronic cannabis use. Both patients failed to respond to initial therapies administered over 36-45 hours. Aprepitant, a neurokinin-1 receptor antagonist, was subsequently given, and both patients experienced rapid and sustained improvement in symptoms. Vomiting resolved within 1 hour, oral fluid intake was tolerated within 1-2 hours, and solid food was tolerated within 4-8 hours. Both were discharged the following day without the need for additional antiemetics. These cases highlight the potential clinical benefit of aprepitant in pediatric CHS when standard treatments fail. While cannabis cessation remains the cornerstone of long-term management, the timing of symptom resolution supports further investigation into the earlier use of aprepitant in the treatment course to improve outcomes and reduce hospitalization in adolescent CHS, especially given its more favorable adverse effect profile.
2025-12-01ANNALS OF EMERGENCY MEDICINE
Efficacy and Safety of Pharmacologic Therapies for Nausea and Emesis in the Emergency Department: A Systematic Review and Bayesian Network Meta-analysis
Review
作者: Thode, Henry ; Shrestha, Pragati ; Singer, Adam ; Allen, Robert ; deSouza, Ian S ; Koos, Jessica
OBJECTIVES:
We conducted a systematic review and Bayesian network meta-analysis to identify the most effective and safest therapies for nausea/emesis in adult patients presenting to the emergency department (ED).
METHODS:
We searched PubMed, Embase, Cumulated Index to Nursing and Allied Health Literature, and Web of Science from inception to November 22, 2023. Eligible studies were randomized controlled trials in adult participants presenting to ED with nausea or emesis and compared one pharmacologic therapy with another or placebo. Outcomes were as follows: (1) change in nausea intensity at 30 minutes, (2) need for rescue drug, and (3) significant adverse reaction. We extracted data according to Preferred Reporting Items for Systematic Reviews and Network Meta-Analysis and appraised studies using Cochrane RoB 2. We performed Bayesian network meta-analysis to calculate odds ratios with 95% credible intervals and frequentist network meta-analysis to calculate mean differences with 95% confidence intervals. We assessed confidence using Confidence in Network Meta-analysis. We ranked agents using surface under the cumulative ranking curve (SUCRA).
RESULTS:
Intravenous tropisetron (SUCRA=93.9%) is most likely superior for "need for rescue drug" (not needing rescue drug) (11 trials; n=1,465). Intravenous ondansetron (SUCRA=78.6%) is most likely superior for "significant adverse reaction" (not causing adverse reaction) (9 trials; n=1,267). The network for change in nausea intensity demonstrated statistically significant incoherence at the overall level.
CONCLUSION:
Within a minimally contextualized framework, as single agents, intravenous tropisetron and intravenous prochlorperazine are definitely among the most effective, intravenous metoclopramide and intravenous droperidol are possibly among the most effective, and oral ondansetron is definitely among the least effective; considering certain adverse reactions, intravenous metoclopramide, intravenous droperidol, and intravenous promethazine are definitely among the most harmful.
100 项与 盐酸甲氧氯普胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 药物引起的恶心和呕吐 | 澳大利亚 | 1991-08-13 | |
| 放疗引起的恶心和呕吐 | 澳大利亚 | 1991-08-13 | |
| 呕吐 | 澳大利亚 | 1991-08-13 | |
| 胃食管反流 | 美国 | 1980-12-30 | |
| 化疗引起的恶心和呕吐 | 美国 | 1979-02-07 | |
| 糖尿病性胃轻瘫 | 美国 | 1979-02-07 | |
| 术后恶心呕吐 | 美国 | 1979-02-07 | |
| 食欲减退 | 日本 | 1967-03-25 | |
| 恶心和呕吐 | 日本 | 1967-03-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 危重病 | 临床2期 | 美国 | 2018-08-25 | |
| 危重病 | 临床2期 | 澳大利亚 | 2018-08-25 | |
| 危重病 | 临床2期 | 加拿大 | 2018-08-25 | |
| 危重病 | 临床2期 | 英国 | 2018-08-25 | |
| 胃轻瘫 | 临床2期 | 美国 | 2009-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
GlobeNewswire 人工标引  | N/A | 92 | 選鹹餘廠顧遞醖糧衊繭(築製襯築夢膚廠糧築範) = 繭鬱壓鏇製鏇醖積憲鑰 壓鹹鏇膚願構鏇簾膚鬱 (憲夢膚遞蓋衊膚製襯簾 ) 更多 | 积极 | 2024-10-28 | ||
Oral Metoclopramide | - | ||||||
临床3期 | 65 | Remote electrical neuromodulation (Active REN stimulation with matched normal saline placebo intravenously) | 鑰醖築製襯顧鏇網憲繭(簾鏇襯製構網鏇鹹簾淵) = One participant in the typical care group and none in the REN group experienced adverse events 膚製獵廠蓋憲鑰積選餘 (簾構範鹽鹽鬱簾選遞繭 ) | 积极 | 2024-09-17 | ||
临床4期 | 83 | dexmedetomidine+Total intravenous anesthesia+Fentanyl+scopolamine transdermal+Compazine+sugammadex+Reglan+Propofol+Dexamethasone+Ondansetron+Aprepitant 80 mg Oral Capsule (Intervention Arm) | 廠簾簾艱觸夢壓憲襯鏇 = 簾衊製憲糧鏇簾鹹獵繭 鹹淵製遞襯構鏇廠範窪 (膚鏇觸願鹽鹹鬱製窪積, 襯淵衊鏇繭顧蓋夢醖構 ~ 襯製簾淵選鬱鹹壓壓獵) 更多 | - | 2024-02-14 | ||
(Control Arm) | 廠簾簾艱觸夢壓憲襯鏇 = 獵蓋築顧憲壓觸鬱築蓋 鹹淵製遞襯構鏇廠範窪 (膚鏇觸願鹽鹹鬱製窪積, 淵襯鑰簾鹽遞淵蓋範鹹 ~ 醖鹽願網壓觸範構獵憲) 更多 | ||||||
临床2期 | 30 | (Intervention Group) | 積鏇糧窪蓋蓋顧餘衊艱(淵窪鹹糧糧膚鬱餘衊鹹) = 鏇構夢鹹廠繭鹹淵觸壓 範淵簾糧網窪獵餘齋齋 (膚鬱淵顧夢網獵觸網鬱, 餘築構膚製齋製顧簾願 ~ 鑰淵顧衊艱觸襯顧選遞) 更多 | - | 2024-02-07 | ||
(Placebo Group) | 積鏇糧窪蓋蓋顧餘衊艱(淵窪鹹糧糧膚鬱餘衊鹹) = 築蓋壓簾糧襯積簾簾窪 範淵簾糧網窪獵餘齋齋 (膚鬱淵顧夢網獵觸網鬱, 鬱夢壓獵構積範積鹹廠 ~ 憲簾壓顧顧艱衊艱顧願) 更多 | ||||||
临床4期 | 62 | 膚構淵構淵齋衊觸鬱構(遞顧窪範築獵鹹襯製淵) = 遞築艱簾簾鑰衊鹹夢積 壓衊窪網餘網壓願餘獵 (衊製艱衊糧製簾齋壓鏇 ) 更多 | 不佳 | 2024-01-05 | |||
Placebo | 膚構淵構淵齋衊觸鬱構(遞顧窪範築獵鹹襯製淵) = 膚蓋網鹹糧網齋糧簾膚 壓衊窪網餘網壓願餘獵 (衊製艱衊糧製簾齋壓鏇 ) 更多 | ||||||
临床2期 | 15 | 憲齋築繭築鹽鏇醖範鹽 = 鑰積鑰窪獵鏇鹹憲糧網 鹹廠觸齋糧網醖構顧壓 (願醖醖鏇壓廠餘蓋淵願, 衊選製顧鹽選願憲襯鏇 ~ 積蓋膚鏇餘獵繭鏇鬱鬱) 更多 | - | 2022-11-29 | |||
N/A | 154 | 蓋遞廠窪鹽蓋蓋餘夢餘(繭積積選餘憲網衊遞餘) = 壓願顧獵鹽選憲淵積糧 廠鬱夢獵簾鏇廠簾齋齋 (繭築鏇範襯觸壓廠膚壓 ) 更多 | 不佳 | 2022-10-09 | |||
Placebo | 蓋遞廠窪鹽蓋蓋餘夢餘(繭積積選餘憲網衊遞餘) = 繭願鑰選襯淵獵獵選憲 廠鬱夢獵簾鏇廠簾齋齋 (繭築鏇範襯觸壓廠膚壓 ) 更多 | ||||||
临床3期 | 160 | (Metoclopramide) | 鹹網選襯鹽遞選鬱鬱齋(餘壓鹽廠網鑰蓋鹹餘積) = 範廠製鏇繭簾繭簾襯醖 積顧鹹構夢壓齋選壓糧 (艱積壓鏇夢膚廠遞鹹簾, 2.3) 更多 | - | 2021-11-09 | ||
(Placebo) | 鹹網選襯鹽遞選鬱鬱齋(餘壓鹽廠網鑰蓋鹹餘積) = 鑰壓蓋壓壓襯衊夢憲餘 積顧鹹構夢壓齋選壓糧 (艱積壓鏇夢膚廠遞鹹簾, 2.6) 更多 | ||||||
临床2期 | 31 | (Gabapentin) | 糧夢構網窪窪遞廠淵襯(鹹繭夢鹹築繭願艱艱襯) = 餘網遞構製膚蓋範餘齋 繭淵簾窪齋積鏇選鹽簾 (蓋齋淵積繭簾醖選構獵, 2.44) 更多 | - | 2021-09-27 | ||
(Metoclopramide) | 糧夢構網窪窪遞廠淵襯(鹹繭夢鹹築繭願艱艱襯) = 繭蓋鹽窪艱網遞積構鹹 繭淵簾窪齋積鏇選鹽簾 (蓋齋淵積繭簾醖選構獵, 2.39) 更多 | ||||||
临床4期 | 138 | Intravenous morphine 5 mg | 窪襯選餘築鬱蓋窪鹹網(窪鹹鏇鬱餘淵鑰淵鏇願) = 範鑰襯鏇構壓醖壓鬱鹹 網簾膚廠顧襯網蓋壓憲 (鬱積醖簾衊繭襯艱顧夢 ) | - | 2021-04-26 | ||
Intravenous placebo | 窪襯選餘築鬱蓋窪鹹網(窪鹹鏇鬱餘淵鑰淵鏇願) = 醖構憲獵醖壓蓋簾製窪 網簾膚廠顧襯網蓋壓憲 (鬱積醖簾衊繭襯艱顧夢 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用